In this cohort of AML patients, there were statistically significant differences in the OS (log-rank P = 0.018) and progression-free survival (PFS; log-rank P = 0.004) rates according to AIMP2-DX2 positivity determined by RT-PCR (Fig. 3c, d). This evidence concerns the gene AIMP2 and acute myeloid leukemia.